A Phase 1/2 Study of NM21-1480 (Anti-PDL-1/Anti-4-1BB/Anti-HSA Tri-Specific Antibody) in Adult Patients with Advanced Solid Tumors

Brief description of study

The purpose of the study is to evaluate the safety and immunogenicity of NM21-1480 in specific tumor types. We wish to know the maximum tolerated dose (MTD) and Recommended Phase 2 Dose (RP2D), define the pharmacokinetics (PK), to explore the pharmacodynamics (PD), and to obtain preliminary evidence of the clinical activity of NM21-1480 in adult patients with selected advanced solid tumors. The study drug NM21-1480 is investigational, which means that while it has not been approved by the U.S Food and Drug Administration (FDA), the health authority that gives approval for new medicines to be prescribed in the United States, the FDA has given its permission to test this agent in the current trial.

Clinical Study Identifier: s20-01935
ClinicalTrials.gov Identifier: NCT04442126

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.